Hypotrichosis-Lymphedema-Telangiectasia Syndrome (HLTS) Cell Models for Research

Hypotrichosis-Lymphedema-Telangiectasia Syndrome (HLTS) is an ultra-rare genetic disorder with fewer than 1 in 1,000,000 individuals affected worldwide. The condition is characterized by the triad of sparse hair (hypotrichosis), swelling due to lymphatic dysfunction (lymphedema), and dilated blood vessels (telangiectasia). While not a malignant disease, HLTS significantly impacts quality of life and can lead to recurrent infections and psychosocial challenges. There is no cure, and current management is symptomatic. The rarity of the disease underscores the need for accurate genetic models to study pathophysiology and test potential therapies.

HLTS serves as an excellent model for studying lymphatic and vascular development, as well as the role of transcription factors in these processes. The disease is primarily caused by mutations in the SOX18 gene, which encodes a transcription factor critical for lymphangiogenesis and angiogenesis. Research on HLTS can provide insights into more common conditions such as lymphedema, vascular malformations, and even cancer metastasis, where lymphatic involvement is key. Public datasets and patient registries are limited due to rarity, making gene-edited cell models essential for mechanistic studies.

Although HLTS is not a cancer, the pathways involved are relevant to oncogenic processes. The major pathways include:

• • VEGF-C/VEGFR-3 signaling: SOX18 regulates the expression of VEGF-C and VEGFR-3, which are critical for lymphatic endothelial cell proliferation and migration. Dysregulation leads to impaired lymphangiogenesis.
• • NOTCH signaling: SOX18 interacts with the NOTCH pathway to control arterial-venous specification and lymphatic valve formation.
• • Wnt/β-catenin signaling: SOX18 can modulate Wnt signaling, affecting cell fate decisions during vascular development.

Data compiled from ClinVar and literature.

Key signaling networks deregulated in HLTS include:

• • Lymphangiogenic signaling: SOX18 → VEGF-C → VEGFR-3 → PI3K/AKT and MAPK/ERK pathways, promoting lymphatic endothelial cell survival and proliferation.
• • Angiogenic signaling: SOX18 also regulates VEGF-A, affecting blood vessel formation.
• • Cell adhesion and migration: SOX18 controls expression of integrins and matrix metalloproteinases, impacting endothelial cell migration.
• • Transcriptional regulation: SOX18 interacts with other transcription factors (e.g., PROX1, FOXC2) to orchestrate lymphatic gene expression.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate lymphatic vessel formation and are valuable for studying HLTS pathophysiology.

• • Genetically engineered mouse models (GEMMs): Sox18 knockout mice exhibit defective lymphatic development and hair loss, mimicking HLTS.
• • Induced models: Morpholino-based knockdown in zebrafish has been used to study SOX18 function.
• • Patient-derived xenografts (PDX): Not applicable for HLTS as it is not a tumor, but patient-derived lymphatic endothelial cells can be xenografted to study vessel formation.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific SOX18 mutations. For example:

• • SOX18 knockout cell lines: Generated by introducing frameshift mutations, leading to complete loss of function. These are useful for studying the impact of SOX18 loss on lymphatic gene expression.
• • SOX18 point-mutation knock-in lines: Mimic patient-specific missense mutations (e.g., p.Arg75Pro) to study dominant-negative effects.
• • Reporter lines: SOX18 promoter-driven fluorescent reporters allow real-time monitoring of SOX18 activity.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems for drug screening and functional studies.

Gene-edited cell lines are instrumental in validating the function of SOX18 and other genes in lymphatic biology. For instance, SOX18 knockout in lymphatic endothelial cells leads to downregulation of PROX1 and VEGFR-3, confirming their role in the SOX18 regulatory network. Knock-in of patient mutations can reveal dominant-negative effects, providing insights into disease mechanisms.

Isogenic pairs (wild-type vs. SOX18 mutant) are used in high-throughput screens to identify compounds that rescue lymphatic function. For example, small molecules that upregulate VEGFR-3 expression could be potential therapeutic leads. Additionally, gene-edited cells can be used to test drug resistance in lymphatic malformations.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, are lethal only in SOX18-mutant cells. This approach can uncover novel therapeutic targets and biomarkers for HLTS. For example, targeting genes in the VEGF-C pathway might selectively kill mutant cells.